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Copper(II) thiosemicarbazone complexes induce
marked ROS accumulation and promote
nrf2-mediated antioxidant response in highly
resistant breast cancer cells†
Angela Sîrbu,a Oleg Palamarciuc,a Maria V. Babak,*b Jia Min Lim,b Kateryna Ohui,c
Eva A. Enyedy,d Sergiu Shova,e Denisa Darvasiová,f Peter Rapta,f Wee Han Ang*b and
Vladimir B. Arion*c
A series of water-soluble sodium salts of 3-formyl-4-hydroxybenzenesulfonic acid thiosemicarbazones
(or sodium 5-sulfonate-salicylaldehyde thiosemicarbazones) containing diﬀerent substituents at the
terminal nitrogen atom (H, Me, Et, Ph) and their copper(II) complexes have been prepared and character-
ised by elemental analysis, spectroscopic techniques (IR, UV-vis, 1H NMR), ESI mass spectrometry, X-ray
crystallography and cyclic voltammetry. The proligands and their copper(II) complexes exhibit moderate
water solubility and good stability in aqueous environment, determined by investigating their proton dis-
sociation and complex formation equilibria. The copper(II) complexes showed moderate anticancer
activity in established human cancer cell lines, while the proligands were devoid of cytotoxicity. The
anticancer activity of the copper(II) complexes correlates with their ability to induce ROS accumulation in
cells, consistent with their redox potentials within the biological window, triggering the activation of
antioxidation defense mechanisms in response to the ROS insult. These studies pave the way for the
investigation of ROS-inducing copper(II) complexes as prospective antiproliferative agents in cancer
chemotherapy.
Introduction
Thiosemicarbazones (TSCs) are well-known for their broad
spectrum of biological activity.1–5 p-Acetylaminobenzaldehyde
thiosemicarbazone was used to treat tuberculosis after the
Second World War,6 while 2-formylpyridine thiosemicarbazone
was the first discovered representative of this class of com-
pounds with potent anticancer activity.7 To date, the 3-amino-
pyridine-2-carboxaldehyde thiosemicarbazone (Triapine)
remains one of the most extensively studied TSC for cancer
chemotherapy.8 Although Triapine entered a number of clini-
cal trials,9 it was later abandoned due to severe side-eﬀects
and limited response to specific cancer types.10–14 Two promis-
ing TSCs, namely, di-2-pyridylketone 4-cyclohexyl-4-methyl-3-
thiosemicarbazone (DpC) and (E)-N′-(6,7-dihydroquinolin-8
(5H)-ylidene)-4-(pyridin-2-yl)piperazine-1-carbothiohydrazide
(COTI-2) entered clinical trials last year,15,16 rekindling interest
in this class of therapeutically-useful compounds. Many TSCs
including Triapine and DpC exhibit excellent chelating pro-
perties with biologically-relevant transition metal ions, such as
iron(II/III), copper(II) and zinc(II).17 The coordination of these
tridentate TSCs to metal ions might result in metal complexes
with enhanced anticancer properties and altered modes of
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50% probability level (Fig. S1), dependence of absorbance vs. pH, concentration
of the proligand, concentration of copper(II) and calibration curve for the
copper(II)–NaH2L
H system, competition with EDTA at λ = 375 nm (Fig. S2–S6),
details of the crystal structures of 1, 2, 1′ and 3 (Fig. S7–S11), concentration-
eﬀect curves (Fig. S12), crystal data and details of data collection, bond lengths
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action. Because malignant cells require higher amounts of
essential metal ions than normal cells as a consequence of
their high metabolism and proliferation levels, coordination of
metal ions could be a strategy to traﬃck TSCs into cancer
cells.18,19 At the same time, copper(II) complexes are promising
anticancer agents,20 often exhibiting very high antiproliferative
activity in vitro. In particular, copper(II) complexes with acyl
diazine TSCs bearing a N4-azabicyclo[3.2.2]-nonane group
showed cytotoxic activity against colon adenocarcinoma HT-29
cells and human acute lymphoblastic leukemia CCRF-CEM
cells with IC50 values ranging from nanomolar to low micro-
molar concentrations.21
Despite the high cytotoxicity of TSCs and their copper(II)
complexes in vitro, their low water solubility and high in vivo
toxicity limit their application as anticancer agents.22 New
metal complexes of TSCs with enhanced aqueous solubility are
highly desirable.23 We recently showed that 2-hydroxybenz-
aldehyde (or salicylaldehyde) thiosemicarbazone (STSC) can be
coupled to L- or D-proline (Pro) leading to highly water-soluble
compounds.24 Although these new TSC derivatives exerted
only moderate cytotoxic eﬀects in ovarian carcinoma CH1
cells, their coordination to copper(II) resulted in significant
increase in cytotoxicity. To access water-soluble TSCs and their
corresponding metal complexes, we recently extended the strat-
egy to utilization of sulfonated salicylaldehyde sodium salt
for condensation reactions with 4N-substituted thiosemicarb-
azides followed by complexation with copper(II). While the
nickel(II) derivative with 5-sulfonate-salicylalehyde thiosemicar-
bazone has been reported many years ago,25,26 copper(II) com-
plexes with this type of thiosemicarbazones have been
reported only quite recently.27,28 Second row transition metal
complexes Na[Pd(LH)(PPh3)] and Na[Pd(L
H)PTA] (PTA = 1,3,5-
triaza-7-phosphaadamantane) were described as eﬃcient cata-
lyst precursors in the Suzuki–Miyaura cross-coupling reactions
of phenylboronic acids with aryl halides in aqueous solution.29
Herein we report on the synthesis of four water-soluble
sodium 5-sulfonate-salicylalehyde TSCs with diﬀerent substitu-
ents at the terminal nitrogen atom of the thiosemicarbazide
moiety, namely, H, Me, Et, Ph, two of which to our knowledge
have never been reported previously, as well as the synthesis of
their corresponding copper(II) complexes (Chart 1). We discuss
the structural features and electrochemical behaviour of the
complexes, as well as their antiproliferative activity in human
cancer cell lines (A2780, A2780cis, MCF-7 and MDA-MB-231)
relative to their toxicity in healthy embryonic kidney cell line.
We also shed light on their mechanism of action, specifically
their capacity to induce ROS intracellularly as well as sub-
sequent cellular responses.
Experimental section
All reagents were used as purchased from commercial suppli-
ers. 5-Sulfonate-salicylaldehyde sodium salt was synthesised
by using reported protocols.30,31 All utilised solvents were
HPLC grade and used without further purification.
NaH2L
H·1.5H2O
A mixture of thiosemicarbazide (0.91 g, 10.0 mmol) and
sodium 5-sulfonate-salicylaldehyde (2.24 g, 10 mmol) in
MeOH (30 ml) was refluxed for 1 h. The reaction mixture
changed during the reaction from yellow to colourless. After
cooling to 4 °C the white precipitate was separated by fil-
tration, washed with cold MeOH and dried in vacuo. Yield:
2.9 g, 97.5%; no m.p., decomposition without melting, onset
at 225 °C. Calcd for C8H8N3NaO4S2·1.5H2O (Mr = 324.31), %: C,
29.63; H, 3.42; N, 12.96; S, 19.77. Found, %: C, 29.79; H, 3.56;
N, 12.99; S, 20.01. 1H NMR (500.10 MHz, DMSO-d6): δ = 11.37
(s, 1H, NNHCS), 10.04 (br. s, 1H, OH), 8.37 (s, 1H, CHvN),
8.10 (s, 1H, NH2), 7.95 (s, 1H, HAr), 7.74 (s, 1H, NH2), 7.47 (dd,
J = 8.5, 2.2 Hz, 1H, HAr), 6.81 (d, J = 8.5 Hz, 1H, HAr) ppm.
13C
{1H} NMR (125.76 MHz, DMSO-d6): δ = 178.1, 156.9, 141.2,
Chart 1 Line drawings structures of thiosemicarbazones NaH2L
R, as well as of their copper(II) complexes.
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140.4, 129.3, 124.8, 119.2, 115.6 ppm. FT-IR: ν = 1621, 1525,
1175, 1112, 1038, 833, 660, 595 cm−1. ESI-MS (negative): m/z
274 [H2L
H]−. UV-vis (DMSO), λmax, nm (ε, M
−1 cm−1): 344
(46 000), 317 (31 600), 304sh.
NaH2L
Me·1.25H2O
A mixture of 4-methylthiosemicarbazide (1.05 g, 10.0 mmol)
and sodium 5-sulfonate-salicylaldehyde (2.24 g, 10 mmol) in
MeOH (30 ml) was refluxed for 1 h. The reaction mixture
changed during the reaction from yellow to colourless. After
cooling to 4 °C the white precipitate was separated by fil-
tration, washed with cold MeOH and dried in vacuo. Yield:
3.1 g, 95.8%; no m.p., decomposition without melting, onset
at 280 °C. Calcd for C9H10N3NaO4S2·1.25H2O (Mr = 333.83), %:
C, 32.38; H, 3.77; N, 12.59; S, 19.21. Found, %: C, 32.46; H,
3.50; N, 12.52; S, 19.43. 1H NMR (500.10 MHz, DMSO-d6): δ =
11.38 (s, 1H, NNHCS), 10.02 (br. s, 1H, OH), 8.39 (s, 1H,
CHvN), 8.32 (d, J = 4.6 Hz, 1H, NHMe), 8.00 (d, J = 2.0 Hz, 1H,
HAr), 7.46 (dd, J = 8.4, 2.2 Hz, 1H, HAr), 6.80 (d, J = 8.5 Hz, 1H,
HAr), 3.02 (d, J = 4.6 Hz, 3H) ppm.
13C{1H} NMR (125.76 MHz,
DMSO-d6): δ = 178.1, 156.8, 140.9, 140.7, 129.3, 124.7, 119.5,
115.6, 31.4 ppm. FT-IR: ν = 1618 1568, 1195, 1113, 1072, 842,
823, 660, 605 cm−1. ESI-MS (negative): m/z 288 [H2L
Me]−. UV-
vis (DMSO), λmax, nm (ε, M
−1 cm−1): 344 (23 380), 330sh, 312
(20 250), 302sh.
NaH2L
Et·0.75H2O
A mixture of 4-ethylthiosemicarbazide (1.2 g, 10.0 mmol) and
sodium 5-sulfonate-salicylaldehyde (2.24 g, 10 mmol) in
MeOH (30 ml) was refluxed for 1 h. The reaction mixture
changed during the reaction from yellow to colourless. After
cooling to 4 °C the white precipitate was separated by fil-
tration, washed with cold MeOH and dried in vacuo. Yield:
3.25 g, 96.0%; no m.p., decomposition without melting, onset
at 260 °C. Calcd for C10H12N3NaO4S2·0.75H2O (Mr = 338.85),
%: C, 35.44; H, 4.02; N, 12.40; S, 18.93. Found, %: C, 35.27; H,
3.75; N, 12.65; S, 19.08. 1H NMR (500.10 MHz, DMSO-d6): δ =
11.33 (s, 1H, NNHCS), 10.05 (br. s, 1H, OH), 8.40 (s, 1H,
CHvN), 8.35 (t, J = 5.9 Hz, 1H, NHCH2), 7.99 (d, J = 2.1 Hz,
1H, HAr), 7.47 (dd, J = 8.4, 2.2 Hz, 1H, HAr), 6.80 (d, J = 8.4 Hz,
1H, HAr), 3.68–3.52 (m, 2H, NHCH2), 1.15 (t, J = 7.1 Hz,
CH2CH3, 3H) ppm.
13C{1H} NMR (125.76 MHz, DMSO-d6): δ =
178.1, 157.0, 140.7, 140.5, 129.3, 124.8, 119.7, 115.3, 38.8,
15.1 ppm. FT-IR: ν = 1535, 1175, 1039, 942, 837, 734, 666,
607 cm−1. ESI-MS (negative): m/z 302 [H2L
Et]−. UV-vis (DMSO),
λmax, nm (ε, M
−1, cm−1): 343 (55 700), 313 (38 400), 302sh.
NaH2L
Ph·1.5H2O
A mixture of 4-phenylthiosemicarbazide (1.67 g, 10.0 mmol)
and sodium 5-sulfonate-salicylaldehyde (2.24 g, 10.0 mmol) in
MeOH (30 ml) was refluxed for 1 h. The reaction mixture
changed during the reaction from yellow to colourless. After
cooling to 4 °C the white precipitate was separated by fil-
tration, washed with cold MeOH and dried in vacuo. Yield:
3.8 g, 95.0%; no m.p., decomposition without melting, onset
at 211 °C. Calcd for C14H12N3NaO4S2·1.5H2O (Mr = 400.41), %:
C, 41.99; H, 3.78; N, 10.49; S, 16.02. Found, %: C, 41.93; H,
3.63; N, 10.46; S, 16.44. 1H NMR (500 MHz, DMSO-d6): δ =
11.72 (s, 1H, NNHCS), 10.08 (s, 1H, OH), 8.49 (s, 1H, CHvN),
8.07 (s, 1H, NHPh), 7.55 (d, J = 7.5 Hz, 1H, HAr), 7.49 (dd, J =
8.5, 2.2 Hz, 1H, HAr), 7.42–7.31 (m, 2H, HAr), 7.19 (t, J = 7.4 Hz,
1H, HAr) 6.82 (d, J = 8.5 Hz, 1H, HAr).
13C{1H} NMR (100 MHz,
DMSO-d6): δ = 176.3, 157.1, 141.4, 140.5, 139.7 129.5, 128.5,
126.0, 125.6, 125.2 119.3, 115.6 ppm. FT-IR: ν = 1609, 1542,
1192, 1106, 1031, 782, 696, 656 cm−1. ESI-MS (negative): m/z
350 [H2L
Ph]−. λmax, nm (ε, M
−1 cm−1): 346 (75 400), 315
(56 700), 304sh.
[CuII(HLH)(DMSO)2] (1)
To a warm solution of NaH2L
H·1.5H2O (0.32 g, 1.0 mmol) in
DMSO (10 ml) was added dropwise a solution of CuSO4·5H2O
(0.25 g, 1.0 mmol) in DMSO (5 ml). The reaction mixture was
stirred at 100 °C for 30 min and allowed to cool and stand at
room temperature. After 3 days a green crystalline product was
separated by filtration, washed with DMSO (2 ml) and dried
in vacuo. Yield: 0.40 g, 81.0%. Calcd for C12H19CuN3O6S4, %: C,
29.23; H, 3.88; N, 8.52; S, 26.01. Found, %: C, 28.88; H, 3.79;
N, 8.17; S, 26.34. FT-IR: ν = 1603, 1524, 1457, 1394, 1330, 1214,
1163, 1104 1017, 947, 826 cm−1. ESI-MS (positive): m/z 437
[CuNa(HLH)(DMSO)]+, 415 [Cu(H2L
H)(DMSO)]+. UV-vis
(DMSO), λmax, nm (ε, M
−1 cm−1): 604 (400), 568 (380), 383sh,
331sh, 315 (80 700). Single crystals suitable for X-ray crystallo-
graphic study were grown as follows: a mixture of
NaH2L
H·1.5H2O (3.2 mg) and CuSO4·5H2O (2.5 mg) were dis-
solved in water (1 ml) on a watch glass. Green solution gener-
ated needle-like crystals of X-ray diﬀraction quality, which
proved to have the composition [Cu(LH)(H2O)2][Cu(L
H)(H2O)]
(1′) (see Fig. S1, ESI†).
[CuII(HLMe)(DMSO)2] (2)
To a warm solution of NaH2L
Me·1.25H2O (0.33 g, 1.0 mmol) in
DMSO (10 ml) was added dropwise a solution of CuSO4·5H2O
(0.25 g, 1.0 mmol) in DMSO (5 ml). The reaction mixture was
stirred at 100 °C for 30 min. Then it was cooled and allowed to
stand at room temperature. After 5 days the green crystalline
product was separated by filtration, washed with DMSO (2 ml)
and dried in vacuo. Yield: 0.40 g, 81.0%. C13H21CuN3O6S4: C,
30.79; H, 4.17; N, 8.29; S, 25.29. Found, %: C, 30.63; H, 4.21;
N, 8.24; S, 25.16. FT-IR: ν = 1604, 1213, 1156, 1015, 948, 820,
708, 663 cm−1. ESI-MS (positive): m/z 451 [CuNa(HLMe)
(DMSO)]+, 429 [Cu(H2L
Me)(DMSO)]+. UV-vis (DMSO), λmax, nm
(ε, M−1 cm−1): 598 (460), 568 (460), 383sh, 331sh, 320 (13 700).
Single crystals for X-ray diﬀraction study were selected from
the prepared sample.
[CuII(HLEt)(H2O)] (3)
To a warm solution of NaH2L
Et·0.75H2O (0.34, 1.0 mmol) in
water (50 ml) was added dropwise a solution of CuSO4·5H2O
(0.25 g, 1.0 mmol) in water (20 ml). The reaction mixture was
stirred at 80 °C for 30 min. After cooling the solution was
allowed to stand at room temperature for 3 h. Green microcrys-
talline product was separated by filtration, washed with water
Dalton Transactions Paper
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(5 ml) and dried in vacuo. Yield: 0.35 g, 87.0%. Calcd for
C10H15CuN3O6S2 (Mr = 400.92), %: C, 29.96; H, 3.77; N, 10.48;
S, 16.00. Found, %: C, 29.81; H, 3.64; N, 10.33; S, 16.22. The
elemental analysis (CHNS) was carried out on samples dried
in vacuo. FT-IR: ν = 1604, 1535, 1468, 1326, 1192, 1145,
1022, 826 cm−1. ESI-MS (positive): m/z 387 [CuNa(HLEt)]+, 365
[Cu(H2L
Et)]+. UV-vis (H2O), λmax, nm (ε, M
−1 cm−1): 601 (590),
569 (560), 375 (19 000), 320sh, 312sh, 265 (33 700), 250sh, 210
(36 800).
[CuII(HLPh)(H2O)]·0.65H2O (4)
To a warm solution of NaH2L
Ph·1.5H2O (0.40 g, 1.0 mmol) in
water (50 ml) was added dropwise a solution of CuSO4·5H2O
(0.25 g, 1.0 mmol) in water (20 ml). The reaction mixture was
stirred at 80 °C for 30 min. After cooling the solution was
allowed to stand at room temperature for 3 h. Green microcrys-
talline product was separated by filtration, washed with water
(5 ml) and dried in vacuo. Yield: 0.38 g, 86.0%: Calcd for
C14H11CuN3O4S2·1.65H2O (Mr = 442.66): C, 37.99; H, 3.26; N,
9.49; S, 14.49. Found, %: C, 37.68; H, 2.99; N, 9.40; S, 14.45.
FT-IR: ν = 1602, 1111, 1026, 832 cm−1. ESI-MS (positive): m/z
457 [CuNa2(L
Ph)]+. UV-vis (H2O), λmax, nm (ε, M
−1 cm−1): 604
(620), 567 (605), 382 (44 300), 325 (53 300), 268 (53 100), 237
(83 400).
X-ray crystallography
X-ray diﬀraction measurements for 1 and 2 were carried out
with an Oxford-Diﬀraction XCALIBUR E CCD diﬀractometer
equipped with graphite-monochromated MoKα radiation.
Single crystals were positioned at 40 mm from the detector
and 352, and 370 frames were measured each for 10, and 5 s
over 1° scan width for 1, and 2, respectively. Intensity data for
1′ were collected with Oxford Diﬀraction SuperNova diﬀrac-
tometer using hi-flux micro-focus Nova CuKα radiation. The
single crystal was positioned at 49 mm from the detector and
964 frames were measured each for 2 s over 1° scan width. The
unit cell determination and data integration were carried out
using the CrysAlis package of Oxford Diﬀraction.32 X-ray data
collection for 3 was performed on a Bruker D8 VENTURE CCD
diﬀractometer. A single crystal was positioned at 79 mm from
the detector, and 6347 frames were measured, each for 26 s
over 2° scan width. The structures were solved by direct
methods using Olex2 33 and refined by full-matrix least-
squares on F2 with SHELXL-97 34 using an anisotropic model
for non-hydrogen atoms. All H atoms were introduced in ideal-
ised positions (dCH = 0.96 Å) using the riding model with their
isotropic displacement parameters fixed at 120% of their
riding atom. The positional parameters of disordered DMSO
ligand in 3 were refined using available tools (PART, DFIX, and
SADI) of SHELXL97 and the combined anisotropic/isotropic
refinement has been applied for non-hydrogen atoms. The
molecular plots were drawn using the Olex2 program. The crys-
tallographic data and refinement details are quoted in
Table S1,† while bond lengths and angles are summarised in
Table S2.† CCDC – 1497276 (1), CCDC – 1497277 (2), CCDC –
1497278 (1′) and CCDC – 1497279 (3) contain the supplemen-
tary crystallographic data for this contribution.
Spectrophotometric measurements
UV-vis spectrophotometric studies were carried out with a
CARY 300 Agilent spectrophotometer in the 200–800 nm inter-
val. The path length was 1 cm. Spectrophotometric titrations
were performed on samples containing the proligands at
40 μM concentration by a NaOH solution in the presence of
0.1 M NaCl at 25.0 ± 0.1 °C. Complex formation with copper(II)
was studied by the methods of molar ratio and continuous
variation at pH 5.75. For the constant pH value of the samples
an acetate buﬀer solution was used. The pH value was
measured/checked with a pH meter I-160 with accuracy of
±0.005. The concentration of the proligand or the metal ion
was constant (48 μM), while that of the other component was
varied in the case of the molar ratio method. Various metal-to-
ligand ratios were used in the case of the Job’s method35 and
the sum of the concentrations of the metal ion and the ligand
was constant (120 μM).
The conditional stability constants (β′) of the investigated
complexes were calculated using the general formula:
β′ ¼ ½complex½M½ligand and were obtained at pH 5.75 via the displace-
ment reaction with ethylenediaminetetraacetic acid (EDTA). In
the competition experiments the samples contained 50 μM
copper(II), 50 μM TSC ligand, and the concentration of EDTA
was varied in the range from 0 to 75 μM. Proton dissociation
constants of proligands, conditional stability constants of the
metal complexes and the individual spectra of the species were
calculated by the computer program PSEQUAD.36 The overall
stability constants of the [CuLR]− complexes (β) were calculated
from the conditional stability constants: β = β′ × αH, where αH =
1 + ([H+] × 10pK1) and [H+] = 10−5.75 M.
Cyclic voltammetry
Cyclic voltammetric experiments with 0.5 mM solutions of 1–4
in 0.1 M nBu4NPF6 (puriss quality from Fluka; dried under
reduced pressure at 70 °C for 24 h before use) supporting elec-
trolyte in DMSO (SeccoSolv max. 0.025% H2O, Merck) were per-
formed under argon atmosphere using a three electrode
arrangement with platinum wire as working and counter elec-
trodes, and silver wire as pseudoreference electrode. Ferrocene
served as the internal potential standard. A Heka PG310USB
(Lambrecht, Germany) potentiostat with a PotMaster 2.73 soft-
ware package served for the potential control in voltammetric
studies. The analytical purity grade NaCl (Slavus Ltd,
SK-Bratislava) and distilled and deionised water were used for
preparation of aqueous solutions of the investigated copper(II)
complexes. As a supporting electrolyte 0.1 M NaCl in
unbuﬀered aqueous solutions was used. Cyclic voltammetric
experiments were performed under argon atmosphere using a
three electrode arrangement with a platinum wire as the
working electrode and counter electrodes. A miniature Ag/AgCl
gel reference electrode from Pine Research Instrumentation
(USA) was used for aqueous solutions.
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Cell lines and culture conditions
Human breast cancer cells MCF-7 and MDA-MB-231, human
ovarian carcinoma cells A2780 and A2780cis, and human
embryonic kidney cells HEK293 were obtained from ATCC.
A2780 and A2780cis cells were cultured in RPMI 1640 medium
containing 10% fetal bovine serum (FBS). MCF-7,
MDA-MB-231 and HEK293 were cultured in DMEM medium
containing 10% FBS. Adherent MDA-MB-231 cells were grown
in Falcon tissue culture 75 cm2 flasks and all other cells were
grown in tissue culture 25 cm2 flasks (BD Biosciences,
Singapore). All cell lines were grown at 37 °C in a humidified
atmosphere of 95% air and 5% CO2. All drug stock solutions
were prepared in DMSO and the final concentration of DMSO
in medium did not exceed 1% (v/v) at which cell viability was
not inhibited. The amount of actual Cu concentration in the
stock solutions was determined by ICP-OES.
Inhibition of cell viability assay
The cytotoxicity of the compounds was determined by colori-
metric microculture assay (MTT assay). The cells were har-
vested from culture flasks by trypsinisation and seeded into
Cellstar 96-well microculture plates (Greiner Bio-One) at the
seeding density of 6000 cells per well. After the cells were
allowed to resume exponential growth for 24 h, they were
exposed to drugs at diﬀerent concentrations in media for 72 h.
The drugs were diluted in complete medium at the desired
concentration and 100 μl of the drug solution was added to
each well and serially diluted to other wells. After exposure for
72 h, drug solutions were replaced with 100 μL of MTT in
media (5 mg ml−1) and incubated for additional 45 min.
Subsequently, the medium was aspirated and the purple for-
mazan crystals formed in viable cells were dissolved in 100 μl
of DMSO per well. Optical densities were measured at 570 nm
with a microplate reader. The quantity of viable cells was
expressed in terms of treated/control (T/C) values by compari-
son to untreated control cells, and 50% inhibitory concen-
trations (IC50) were calculated from concentration-eﬀect curves
by interpolation. Evaluation was based on means from at least
three independent experiments, each comprising six replicates
per concentration level.
Measurement of cellular reactive oxygen species by
flow cytometry
MDA-MB-231 cells were harvested from culture flasks by trypsi-
nisation and 1 mL of cell solution was transferred to 1.5 ml
microtubes (2 × 105 cells per ml). The cells were centrifuged
(5 min, 2.5 × 103 rpm) and washed with 1 mL of Hank’s
Balanced Salt Solution (HBSS) and centrifuged again (5 min,
2.5 × 103 rpm). Supernatant was replaced with 20 µM of 2′,7′-
dichlorodihydrofluorescein diacetate (H2DCF-DA) in HBSS and
the cells were incubated for 10 min at 37 °C in the darkness
on an Eppendorf Thermomixer for probe activation. The cells
were then centrifuged (5 min, 2.5 × 103 rpm) and the super-
natant was replaced with the drug solutions in colourless
Dubelco’s Modified Eagle Medium (DMEM) without FBS at
desired concentrations. The cells were then incubated with
drug solutions for 5 h (37 °C) in the darkness on an Eppendorf
Thermomixer. tert-Butylhydroperoxide (TBHP; 50 µM) was
used as a positive control and trolox was used as ROS scaven-
ger. Trolox samples were pretreated with trolox (100 µM) for
30 min before they were cotreated with indicated drug at
desired concentrations and trolox (100 µM) for 5 h, similarly
as described above. After 5 h, the cell solutions were immedi-
ately strained with a 60 µM cell strainer prior to analysis with
BD LSRFortessa Cell Analyser. 0.46 g L−1 propidium iodide (PI)
was added to the strained samples to identify the dead cells.
The data was processed and exported using BD FACSDiva 6.2.
Quantitative analysis was performed using Summit software.
The quantity of ROS species was expressed in terms of treated/
control (T/C) values by comparison to control cells treated with
H2DCF-DA probe only. Evaluation was based on means from at
least three independent experiments.
Western blot analysis
MDA-MB-231 cells were seeded into Cellstar 6-well plates
(Greiner Bio-One) at a density of 500 000 cells per well. After
the cells were allowed to resume exponential growth for 24 h,
they were exposed to 1–4 and NaH2L
Et at diﬀerent concen-
trations for 24 h. The cells were washed twice with 1 ml of PBS
and lysed with lysis buﬀer [100 μL, 1% IGEPAL CA-630,
150 mM NaCl, 50 mM Tris-HCl (pH 8.0), protease inhibitor]
for 5–10 min at 4 °C. The cell lysates were scraped from the
wells and transferred to separate 1.5 mL microtubes. The
supernatant was then collected after centrifugation (13 000
rpm, 4 °C for 15 min) and total protein content of each sample
was quantified via Bradford’s assay. Equal quantities of
protein (50 µg) were reconstituted in loading buﬀer [5% DDT,
5× Laemmli Buﬀer] and heated at 105 °C for 10 min.
Subsequently, the protein mixtures were resolved on a 10%
SDS-PAGE gel by electrophoresis (90 V for 30 min followed by
120 V for 60 min) and transferred onto a nitrocellulose mem-
brane (200 mA for 2 h). The protein bands were visualised with
Ponceau S stain solution and the nitrocellulose membranes
were cut into strips based on the protein ladder. The mem-
branes were washed with a wash buﬀer (0.1% Tween-20 in 1×
DPBS) three times for 5 min. Subsequently, they were blocked
in 5% (w/v) non-fat milk in wash buﬀer (actin antibody) or 5%
BSA (w/v) in wash buﬀer (p21 and nrf2 antibodies) for 1 h and
subsequently incubated with the appropriate primary anti-
bodies in 2% (w/v) non-fat milk in wash buﬀer (actin antibody)
or 5% BSA (w/v) in wash buﬀer (p21 and nrf2 antibodies) at
4 °C overnight. The membranes were washed with a wash
buﬀer 3 times for 7 min. After incubation with horseradish
peroxidase-conjugated secondary antibodies (room tempera-
ture, 1.5 h), the membranes were washed with a wash buﬀer 4
times for 5 min. Immune complexes were detected with
Luminata HRP substrates (Merck Millipore) and analysed
using enhanced chemiluminescence imaging (PXi,Syngene).
Actin was used as a loading control. The following antibodies
were used: p21 (F-5) and nrf2 (sc13032) from Santa Cruz
Biotechnologies, β-Actin (ab75186) from Abcam, ECL
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Antirabbit IgG (NA934 V) and ECL Antimouse IgG (NA931)
from GE Healthcare Life Sciences. All antibodies were used at
1 : 500 dilutions except for actin (1 : 10 000), anti-mouse and
anti-rabbit (1 : 5000).
Results and discussion
Synthesis of NaH2L
H, NaH2L
Me, NaH2L
Et and NaH2L
Ph and
corresponding copper(II) complexes
Sodium salts of 3-formyl-4-hydroxybenzenesulfonic acid TSCs
NaH2L
H, NaH2L
Me, NaH2L
Et and NaH2L
Ph (Chart 1) were
prepared as proligands via the condensation reaction between
4-substituted thiosemicarbazide and sodium 5-sulfonate-
salicylaldehyde in boiling MeOH. The synthesis of NaH2L
H
and NaH2L
Ph is well-documented in the literature,31 while the
other two derivatives to our knowledge have not been reported
previously. The prepared compounds were characterised by
elemental analysis, IR, 1H and 13C NMR spectroscopies and
ESI mass spectrometry. The aldimine resonance was observed
as a singlet at δ 8.37–8.49 ppm in 1H NMR indicating the for-
mation of Schiﬀ bases NaH2L
H, NaH2L
Me, NaH2L
Et and
NaH2L
Ph. Infrared spectra displayed characteristic absorption
bands for CvN bond at 1605–1621 cm−1 and for CvS group
at 814–845 cm−1. The ESI mass spectra measured in the nega-
tive ion mode showed peaks with m/z 274, 288, 302 and 350
which were attributed to [H2L
R]−, where R = H, Me, Et and Ph,
respectively.
[CuII(HLH)(DMSO)2] (1) and [Cu
II(HLMe)(DMSO)2] (2) were
prepared by reactions of NaH2L
H and NaH2L
Me, respectively,
with CuSO4·5H2O in hot DMSO, while [Cu
II(HLEt)(H2O)] (3)
and [CuII(HLPh)(H2O)]·0.65H2O (4·0.65H2O) via the analogous
reactions in water. The formation of 1–4 and their purity were
confirmed by elemental analysis, IR, UV-vis and ESI mass
spectra, as well as by single crystal X-ray diﬀraction analysis in
case of 1–3 (vide infra). The electronic absorption spectra of
1–4 in DMSO showed λmax at 567–604 nm with extinction
coeﬃcients of 380–620 M−1 cm−1, which were attributed to
d–d transitions.
Proton dissociation constants, copper(II) complex formation
and stability in aqueous solution
Structural and spectroscopic characterisation of compounds
are typically performed in the solid state or in organic solvents
and the data obtained do not furnish information regarding
their biotransformation in biological fluids. Investigation of
the speciation processes, especially at physiological pH, is
necessary to elucidate the mechanism of protic equilibria for
the development of more eﬀective chemotherapeutics.
However, such data on TSCs is scarce due to their low aqueous
solubility. In addition, little has been done on investigation of
the thermodynamic stability of metal complexes formed with
salicylaldehyde TSCs in solution. In this work we describe the
proton dissociation equilibrium processes of four TSCs and
spectroscopic properties of the main species involved in those
equilibria, as well as the solution stability of their copper(II)
complexes. Proton dissociation processes of NaH2L
H (Fig. 1,
top) and its terminally-substituted derivatives (NaH2L
Me,
NaH2L
Et and NaH2L
Ph) were studied by UV-vis spectrophoto-
metric titrations in aqueous solution.
Proton dissociation of NaH2L
H was accompanied by charac-
teristic spectral changes upon variation of the pH of the solu-
tion (Fig. 1, bottom left). At acidic pH the aqueous solutions
were colourless and revealed absorption maxima at 302 and
328 nm, typical for aldimine and phenolic chromophore,
respectively. At basic pH values the colour of the solution
Fig. 1 (Top) Proton dissociation steps of 5-sulfonato-salicylaldehyde TSC (H2L
H)−. (Bottom left) Representative UV-vis absorption spectra of
NaH2L
H (cligand = 4.0 × 10
−5 M) at diﬀerent pH values. Inset shows the molar absorbance spectra of the individual species (H2L
H)− and (HLH)2−
obtained by the deconvolution of the recorded spectra. (Bottom right) Dependence of the absorbance of NaH2L
H (×) and NaH2L
Me (○) at 363 nm
from pH together with the simulated curves (dashed lines) (cligand = 3.9 × 10
−5 M).
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changed to light-green and development of a strong absorp-
tion band with a maximum at 367 nm was observed.
NaH2L
H contained two dissociable protons. The sulfonate
group remained deprotonated across the whole pH range
studied due to its strong acidic character, which accounted for
the excellent water solubility of the proligand. The first dis-
sociation step of NaH2L
H was attributed to deprotonation of
the phenolic group represented by pK1, while pK2 was ascribed
to the loss of hydrazinic N2–H-proton of thiosemicarbazide
moiety with the negative charge localised on S-atom via
thione–thiol tautomeric equilibrium (Fig. 1, top). For STSC in
a 30% (w/w) DMSO/water solvent mixture pK1 = 8.84 and pK2 =
12.57 were reported.37 The high pK2 value resulted from the
deprotonation having taken place in a strongly basic medium,
where the accurate determination of pKa would be diﬃcult in
pure aqueous solution because of the error of the glass elec-
trode. Consequently only one pKa value (= pK1) could be deter-
mined for the studied proligands based on the spectral
changes via the deconvolution of the measured spectra (see
Fig. 1, bottom right for the fitting of the measured and calcu-
lated absorbance values in the case of NaH2L
H and NaH2L
Me).
The development of new strong bands with higher λmax values
(367–370 nm) was observed for all proligands due to the depro-
tonation of the phenolic group, which resulted in more
extended conjugated π electron systems. The determined pK1
values were quoted in Table 1. The substituents at the terminal
nitrogen had no measureable influence on pK1. These values
(7.73–7.82) were considerably lower compared to that of the
reference proligand STSC (8.84), what could be explained by
two factors: (i) the large electron withdrawing eﬀect of the sul-
fonate substituent; (ii) the pKa of an anionic base (such as phe-
nolic OH) was increased in the presence of DMSO according to
the Born electrostatic solvent model.38
Upon addition of copper(II) to NaH2L
H the colour of the
solution changed from colourless to light-green across a wide
pH range. This colour change was due to the development of a
charge-transfer absorption band with a maximum at ∼375 nm
indicating complex formation between copper(II) and NaH2L
H.
Fig. 2 shows the electronic absorption spectra of the proligand
in the absence and in the presence of copper(II) ions.
Based on the variation of the absorbance at 375 nm as a
function of pH (Fig. S2†), the optimal window for complex for-
mation between copper(II) and NaH2L
H was determined to be
between pH 5.0 and 6.3. Assuming similar complexation pro-
Table 1 pK1 values of the ligand precursors, spectroscopic parameters for the ligand precursors and the copper(II) complexes, conditional (β’) and
overall (β) stability constants for copper(II) complexes formed with NaH2L
H, NaH2L
Me, NaH2L
Et and NaH2L
Ph
Ligand NaH2L
H NaH2L
Me NaH2L
Et NaH2L
Ph
Absorption maxima of the ligands (λ, nm) 302, 328 302, 328 302, 329 303, 332
367 367 367 370
pK1 7.73 ± 0.02 7.82 ± 0.02 7.79 ± 0.02 7.73 ± 0.04
Absorption maxima Cu(II) complexes (λ, nm) 375 375 375 380
Cu(II)-to-ligand ratio 1 : 1 1 : 1 1 : 1 1 : 1
Optimal window for complex formation (pH) 5.1–6.3 5.3–6.3 5.3–6.3 4.8–6.0
Molar absorptivity of the complex (ε, M−1 cm−1) at λmax 11 812 13 943 14 433 19 233
log β′ (at pH 5.75) [CuLR]− a 12.81 ± 0.06 12.87 ± 0.06 12.77 ± 0.07 13.50 ± 0.04
log β (β = β′ × αH)
b [CuLR]− 14.79 14.94 14.81 15.48
Concentration range in which the Lambert–Beer law is valid (μM) 6–100 10–100 10–100 6–100
aDetermined by UV–vis spectroscopy via competition studies with EDTA. Protonation constants of EDTA and stability constants of its copper(II)
complex are taken from the literature:40 log β values: 10.26 (HL), 16.42 (H2L), 19.09 (H3L), 21.08 (H4L), 18.7 (CuL). log β′ of (CuL): 13.64 at pH
5.75. bCalculation of the overall stability constants of the [CuLR]− complexes (β) from the conditional stability constants (β′ at pH 5.75): β = β′ ×
αH where αH = 1 + ([H
+] × 10pK1); [H+] = 10−5.75.
Fig. 2 Modiﬁcation of the UV-vis spectrum of NaH2L
H (black line) upon addition of copper(II) (grey line) at a constant pH (a) (pH = 5.75; cCu(II) =
60 μM, cligand = 60 μM); and the diﬀerence spectra (b) obtained as the diﬀerence of the measured spectra for the copper(II)–NaH2LH system at
various pH values decreased by those of the relevant ligand spectra. (pH = 3.81–6.37; cCu(II) = 48 μM, cligand = 65 μM).
Dalton Transactions Paper
This journal is © The Royal Society of Chemistry 2017 Dalton Trans., 2017, 46, 3833–3847 | 3839
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 2
7 
Fe
br
ua
ry
 2
01
7.
 D
ow
nl
oa
de
d 
on
 7
/3
/2
01
9 
6:
02
:3
8 
A
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
cesses for our proligands and STSC, the formation of [CuLH]−
complex was expected to occur in slightly acidic-to-neutral pH
range via the (O−,N1,S−) donor atom set.39 At lower pH values
the protonation of the hydrazine N2–H group would be feas-
ible, while in the more basic pH range deprotonation of the co-
ordinated water molecule could take place at the fourth coordi-
nation site resulting in a mixed hydroxido species
[CuLH(OH)]2−.
It is worth noting that the copper(II) complex formed at pH
between 5.0 and 6.3 was stable over time showing a constant
absorption value for >10 h. By exploring the method of con-
tinuous variation (Fig. 3) and that of molar ratios (Fig. S3 and
S4†) we concluded that under these conditions, a 1 : 1 copper(II)-
to-ligand complex is formed in the case of NaH2L
H. The other
three derivatives (NaH2L
Me, NaH2L
Et and NaH2L
Ph) were also
investigated using the same approach to elucidate the eﬀect of
the substituents at the terminal nitrogen of the thiosemicarb-
azide moiety on copper(II) complex formation.
Based on the absorbance values recorded by the method of
molar ratios (using a constant metal ion concentration when
the proligand concentration was varied and vice versa) it could
be concluded that the formation of the complexes is practically
quantitative under the applied conditions, which hindered the
direct determination of the apparent (conditional) formation
constants (β′) of the copper(II) complexes [CuLR]−. Therefore
the conditional formation constants for these complexes were
determined spectrophotometrically by competition reactions
with EDTA at pH = 5.75 (Fig. S6†) using the program
PSEQUAD.36 Notably both the TSC ligand and EDTA form pre-
dominantly monoligand complexes [CuL] under the applied
conditions. In addition, both EDTA and its copper(II) complex
have negligible contribution to the measured absorbance
values at the chosen wavelength (375 nm). These calculations
also provided the average values of the molar absorptivities (ε)
of the TSC complexes formed. The obtained values were sum-
marised in Table 1. The presence of H, alkyl and/or phenyl
substituents at the terminal nitrogen atom of TSCs resulted in
some diﬀerences in the molar absorptivities of the complexes.
In particular for NaH2L
Ph, the conjugation of the phenyl ring
increased the absorption significantly. The conditional stabil-
ity constants were similar to each other reflecting close
binding abilities of the studied TSCs to copper(II) except the
case of the phenyl derivative, which possesses more than half
order of magnitude higher constant. Using the pK1 values
(which are equal to the log KHL protonation constants) the
overall stability constants (β) of the complexes [CuLR]− were
also calculated from the conditional stability constants
(Table 1). The obtained conditional/overall stability constants
reflected formation of highly stable copper(II) complexes with
all four ligands, and the extent of decomposition of these com-
plexes at physiological pH was estimated to be less than 1%
even at concentration ≤1 μM. UV-vis spectra for the copper(II)–
NaH2L
H system were recorded in a wide concentration range (6
to 100 μM) (Fig. S5†) and the linear dependency was indicative
of the high solution stability of the complex at the given pH
value. It is worth mentioning that the [CuL] complex of the
reference compound STSC possesses a much higher overall
stability constant (log β = 19.02) due to its higher pK2 value
which could be determined in the presence of 30% DMSO;
however its conditional stability constant is significantly lower
(log β′ = 9.04) at pH 5.75.37 The studied TSCs with the sulfo-
nate group show the formation of higher stability complexes
compared to STSC.
Solid-state structural analyses
Copper(II) complexes 1, 2, 1′ and 3 were studied by single
crystal X-ray diﬀraction and their solid-state structures are
depicted in Fig. 4. The asymmetric unit of the crystal struc-
tures of 1 and 2 comprised [Cu(HLH)(DMSO)2] and [Cu
II(HLMe)
(DMSO)2], respectively. In both compounds the coordination
of the copper(II) was provided by the ONS-donor set of the
Schiﬀ base ligand and two molecules of DMSO bound via
oxygen atom in equatorial (Cu–O5 1.970(4) Å for 1, 1.972(3) Å
for 2) and apical (Cu–O6 2.560(4) Å for 1, 2.659(9) Å for 2) posi-
tions. The sulfonate group of the ligand in 1 and 2 does not
participate in the coordination to copper(II). Thus the coordi-
nation geometry of the central atom can be described as
slightly-distorted square-pyramidal (τ value39 of 0.098 and
0.111 for 1 and 2, respectively). In contrast to 1 and 2, one of
the sulfonate groups in 1′ (Fig. S1†) plays a bridging function
being coordinated via one of the oxygen atoms to copper(II)
atom of the neighbouring molecule. As a result, 1′ has a dinuc-
lear molecular structure. As in 1, 1′ and 2 the values of τ para-
meters of 0.127 for Cu1A and 0.077 for Cu1B in 3 indicate
square-pyramidal coordination geometry for the central atoms.
Other details of the crystal structures are given in ESI (Fig. S7–
S11†).
Electrochemistry in DMSO
The redox cycling between Cu(II) and Cu(I) states plays an
important role in the biological action of copper, where a
Fenton-like redox chemistry in Cu(I)/Cu(II)/H2O2/O2 systems is
responsible for production of a variety of reactive oxygen
species (ROS) including HO• and O2
•−. Therefore, we investi-
Fig. 3 Absorbance values obtained by the method of continuous vari-
ation in the copper(II)–NaH2L
H system (Job plot). (cCu(II) + cligand =
120.0 μM, pH = 5.75, λ = 375 nm).
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gated the redox behaviour of 1–4 in DMSO, in which all four
compounds exhibited good solubility. Very similar cyclic vol-
tammograms were obtained for 1–3 with the hydrogen or ali-
phatic substituent at the terminal nitrogen atom of the thiose-
micarbazide. The corresponding cyclic voltammograms in
DMSO/nBu4NPF6 at scan rate of 100 mV s
−1 are shown in
Fig. 5 (left). They showed clearly one reduction peak which was
presumed to be metal centred and a strongly shifted re-
oxidation peak for CuI species formed upon reduction.
Complexes 1–3 showed very similar irreversible reduction
peaks at E1pc = −0.81 V vs. Fc
+/Fc0, which were attributed to the
CuII → CuI process. A sharp oxidation peak during the reverse
scan at around −0.3 V vs. Fc+/Fc0 exhibited typical features of a
redissolution process. Consequently, the reduction process in
the region of the first cathodic peak was electrochemically irre-
versible and led to a deposition of the less soluble copper(I)
complexes on the electrode surface. This was also the case for
4, but a marked shift of the first cathodic peak potential to
−1.02 V vs. Fc+/Fc0 was also observed, indicating that the sub-
stitution at the terminal nitrogen atom of the thiosemicarb-
azide with the aromatic phenyl group led to an increase of the
corresponding cathodic potential. It should be noted that
Fig. 4 ORTEP views of a fragment of crystal structures of 1 (top left), 2 (top right) and 3 (bottom) with atom labeling schemes and thermal ellipsoids
drawn at 50% probability level.
Fig. 5 (Left) The cyclic voltammograms of 0.5 mM of samples 1 (black trace), 2 (blue trace), 3 (green trace) and 4 (red trace) in DMSO/nBu4NPF6 at
scan rate of 100 mV s−1. (Right) The cyclic voltammogram of 0.25 mM of 2 in the presence of 0.25 mM ferrocene internal standard in DMSO/
nBu4NPF6 at scan rate of 100 mV s
−1.
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upon redox cycling the cyclic voltammetric response showed
negligible changes in the shape of the corresponding cyclic
voltammograms in the cathodic part confirming the chemical
reversibility of the observed processes. After redissolution of
the copper(I) complex by reoxidation upon the reverse scan the
recovered copper(II) complex could be again reduced at the
same cathodic potential.
Such redox behaviour was characteristic for a variety of
redox active copper(II) complexes and could be explained by a
dual-pathway square reaction scheme41,42 with copper(II) and
copper(I) species of diﬀerent stability, where the electron trans-
fer in Cu(II/I) systems was accompanied by strong changes in
their coordination geometry. In addition to reduction we also
observed a quasireversible redox process in the anodic part of
CVs with the oxidation peak at +0.34 V vs. Fc+/Fc0 as shown for
2 in Fig. 5 (right). The same anodic peak was found for 1 and
3. The height of the corresponding anodic peak was similar to
the cathodic one and also to the ferrocene signal with the
same molar concentration confirming the one electron trans-
fer process in the case of the first oxidation event.
Electrochemistry in water
Analogous redox behaviour with one broad reduction peak
and a strongly shifted reoxidation peak was observed for 1–4
in 0.1 M NaCl unbuﬀered aqueous solutions at scan rate of
100 mV s−1 at platinum working electrode as shown in Fig. 6
(left). It should be noted that we used saturated solutions of
the complexes for cyclic voltammetric studies. The lowest solu-
bility in water was observed for 4, while the highest one for 1.
The corresponding normalised (for clarity) UV-vis spectra of
1–4 in 0.1 M NaCl/H2O are shown in Fig. 6 (right).
The observed potential shifts in the anodic oxidation of 1–4
by replacing aprotic DMSO with proton-donating water
environment were caused by expected diﬀerent energy of sol-
vation for DMSO and H2O and by involvement of protons in
the redox process in water in contrast to the aprotic environ-
ment.43,44 Interestingly, the lowest reduction potential E1pc =
−0.27 V vs. Ag/AgCl was observed for 1 with terminal –NH2
group in the ligand. For comparison, the redox potential in
unbuﬀered aqueous solutions was recalculated vs. Fc+/Fc0
using known redox potential of Ag/AgCl (0.197 V) and ferro-
cene (0.64 V) vs. Standard Hydrogen Electrode (SHE).
Consequently the first cathodic peak potential for 1 in H2O/
NaCl system would correspond to −0.71 V vs. Fc+/Fc0. For 2–4,
very similar cyclic voltammograms were observed with broad
first cathodic peak with the maximum at around −0.35 V vs.
Ag/AgCl (E1pc = −0.79 V vs. Fc
+/Fc0), similar to those found
when DMSO was used as a solvent.
Antiproliferative properties
Copper(II) complexes and corresponding TSCs were tested for
cytotoxicity against a panel of human cancer cell lines includ-
ing breast adenocarcinoma MCF7, ovarian carcinoma (A2780
and A2780cis) human breast adenocarcinoma MDA-MB-231
and noncancerous human embryonic kidney cells (HEK293).
The IC50 values are listed in Table 2 and concentration-eﬀect
curves are depicted in Fig. S12.† The proligands were soluble
in water within the whole concentration range tested but the
coordination to copper(II) decreased their solubility in water
and DMSO significantly and limited the concentration range
that could be used for biological studies.
The antiproliferative activities of copper(II)–TSC complexes
and their corresponding proligands were previously investi-
gated in various cell lines. Many metal-free thiosemicarba-
zones, including Triapine, exhibit very high cytotoxicity up to
nanomolar concentrations,45–48 which was postulated to be
related at least in part to their ribonucleotide reductase inhibi-
tory potential,18 but there are also examples of TSCs with mod-
erate antiproliferative activity.24,42–44 Coordination of TSCs to
copper(II) usually leads to an increase in antiproliferative
activity of the resultant copper(II) complexes.24,47 A notable
exception is copper(II)–Triapine complex which showed a sig-
nificant decrease in anticancer activity when compared to that
of Triapine alone.48
Fig. 6 (Left) The cyclic voltammograms of saturated solutions of samples 1 (black trace), 2 (blue trace), 3 (green trace) and 4 (red trace) in H2O/
NaCl at scan rate of 100 mV s−1. (Right) UV-vis spectra of samples 1 (black trace), 2 (blue trace), 3 (green trace) and 4 (red trace) in H2O/NaCl solu-
tions (dashed lines: an expansion of the small vis bands).
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In this work, with the exception of NaH2L
Ph, TSCs did not
display any cytotoxicities against tested cancer cell lines. Upon
their coordination to copper(II) however, a 10–30-fold increase
of cytotoxicity has been observed. No clear-cut structure–
activity relationships could be established since the copper(II)
complexes were not structurally-analogous. Nevertheless, 1
and 2 with two coordinated DMSO ligands demonstrated
higher cytotoxicities than 3 and 4, which contained aqua
ligands instead of DMSO. Against A2780 ovarian carcinoma
and cisplatin-resistant A2780cisR, the tested complexes exhibi-
ted similar eﬃcacies with 1–2-fold increase of activities in
A2780cisR compared to that in the parental A2780 cell line.
The A2780cisR cell line was derived from A2780 by chronic
exposure to cisplatin and marked by elevated levels of mis-
match repair proteins and gluthatione.49,50 This suggested that
the copper(II) complexes were exerting their cytotoxicities via a
diﬀerent pathway compared to cisplatin, an alkylating agent,
which typically exhibits 10–20-fold diﬀerence between these
cell lines.
Copper(II) complexes are toxic to the normal cells due to
their redox activity and aﬃnity for binding sites typically occu-
pied by other metals (e.g., iron). Therefore, the complexes were
tested against nontumorigenic embryonic kidney cell line
HEK293 as a model of healthy cells. Cu–TSC complexes pre-
viously tested for their antiproliferative activity in the noncan-
cerous murine embryonal fibroblast (NIH/3T3) cell line
showed no particular selectivity towards cancer cells compared
to healthy cells.47 Based on the results of MTT assay, 1–4
demonstrated a slightly decreased cytotoxicity against non-
cancerous cells; however, the determination of the IC50 values
in HEK cells was hindered by moderate solubility of copper(II)
compounds.
ROS induction and activation of antioxidant defense
Copper(II) complexes can initiate Fenton reactions intracellu-
larly resulting in ROS accumulation,51–54 the presumed mech-
anism of biological activity for many copper(II) complexes in
general.48,55,56 Indeed, most reports describe the observed
anticancer activities in terms of the redox potentials of the
copper(II) complexes. The reduction of Cu(II) to Cu(I) occurs in
the presence of the intracellular thiols, such as glutathione
(GSH),57,58 resulting in a depletion of GSH pools. Upon reac-
tion with molecular oxygen, Cu(I) is reoxidised to Cu(II) thereby
generating reactive superoxide radicals (O2
•−) that are detri-
mental to cellular processes.57,59,60 About 25 years ago Petering
et al. demonstrated that copper(II) chelates of 2-formylpyridine
and 4-formylpyridine TSCs were capable of inducing cell
death associated with ROS generation and depletion of
cellular glutathione.60–62 Since then various copper(II)–TSC
complexes were shown to readily react with GSH and induce
oxidative stress.48,63,64 The generation of ROS species also
occurs as a consequence of metabolism, and, antioxidant
systems have been developed by the cells to scavenge ROS as a
defense mechanism. Evidence suggests that cancer cells
underwent ROS stress to drive proliferation and other pro-
cesses required for the development of tumour.65 As a result,
the basal level of oxidative stress in cancer cells is higher than
that in normal cells and therefore, they become vulnerable to
chemotherapeutic agents or redox active agents, such as
copper(II) complexes, which can increase ROS production.
Based on the results of electrochemical experiments, we
expected redox active 1–4 to markedly increase the amount of
ROS in cancer cells. The biologically accessible redox potential
window in cells has a narrow range −0.4 V to +0.8 V vs. NHE
and redox reactions with higher or lower potentials cannot
occur in the cellular environment. As can be seen in Fig. 6, the
reduction potential of all complexes occur within the biologi-
cally accessible window implying that they can be reduced by
GSH and favour generation of radicals. Additionally, the cyclic
voltammograms showed reverse oxidation peaks; therefore, it
was expected that in cancer cells Cu(I) would reoxidise to Cu(II)
promoting Fenton reactions.
ROS accumulation was evaluated in triple-negative highly
resistant breast cancer MDA-MB-231 cell line using cell-per-
meable 2′,7′-dichlorodihydrofluorescein diacetate (H2DCF-DA)
as a probe. This crosses the cell membrane by passive
diﬀusion and is retained in the cell after enzymatic cleavage.
Upon oxidation by ROS, the nonfluorescent H2DCF is con-
verted to highly fluorescent 2′,7′-dichlorofluorescein (DCF) as
an indication of intracellular ROS levels. In order to establish
whether ROS induction could lead to cell death, we detected
ROS species at an early time point 5 h after incubation with
the compounds. The values were normalised to the fluo-
rescence of the untreated cells and presented as fold change
relative to the fluorescence of the cells treated with fluorescent
probe alone. The values of the generated mean fluorescence
were plotted onto a bar chart for easy visualisation (Fig. 7).
tert-Butylhydroperoxide (TBHP; 50 µM), an organic peroxide
was used as a positive control in the ROS assay.
Copper(II) complexes 1–4 demonstrated a significant ROS
induction in a dose-dependent manner already after 5 h of
incubation (Fig. 7A). The level of the generated ROS species
Table 2 Cytotoxicity of the TSC proligands and copper(II) complexes
1–4
Compound A2780
IC50
a (µM)
A2780cis MCF7 MDA-MB-231 HEK293
NaH2L
H >1000 >1000 >1000 >1000 >1000
NaH2L
Me >1000 >1000 >1000 >1000 >1000
NaH2L
Et >1000 >1000 >1000 >1000 >1000
NaH2L
Ph 516 ± 210 >1000 >1000 >1000 >1000
1 56 ± 9 84 ± 14 61 ± 5 97 ± 14 >95
2 30 ± 3 40 ± 3 35 ± 1 >40 >40
3 59 ± 15 106 ± 2 93 ± 9 134 ± 22 >120
4 78 ± 14 134 ± 19 131 ± 5 116 ± 36 >170
Cisplatin 0.60 ± 0.05 11 ± 2 22 ± 7 27 ± 8 4.3 ± 1.0
a 50% inhibitory concentrations (IC50) in human ovarian carcinoma
cell lines A2780 and A2780cis, human breast adenocarcinoma cell line
MCF7, human adenocarcinoma cell line MDA-MB-231 and human
embryonic kidney cell line HEK293, determined by means of the MTT
assay after exposure for 72 h; n.d. means not detected. Values are
means ± standard deviations obtained from at least three independent
experiments.
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was comparable to that of TBHP. All complexes induced
similar amount of ROS under identical conditions, which cor-
related to their similar reduction potentials. In contrast, the
corresponding TSCs did not show any induction of ROS
species (Fig. 7D). In fact, their level of fluorescence was even
lower than the fluorescence of the probe, which indicated the
important role of copper(II) in generation of ROS. Water-
soluble vitamin E analogue trolox (100 µM) was known to
protect cells against oxidative stress and used in this assay as a
ROS scavenger.66 The cells were preincubated with trolox for
30 min and exposed to 1–4 for additional 5 h. As seen from
Fig. 7C, intracellular fluorescence levels significantly decreased
in the presence of trolox, even after TBHP exposure, indicating
eﬀective ROS quenching. These results suggest that copper(II)
complexes act by induction of critical levels of reactive oxygen
species.
Following ROS insult, cells can activate their antioxidant
defense system as a survival mechanism, which will result in
the expression of the nrf2 transcription factor. Nrf2 regulates a
number of downstream genes responsible for cell growth and
apoptosis, DNA repair and the inflammatory response. The
role of these downstream genes is to counteract the deadly
eﬀects of excessive ROS which, when left unchecked, will lead
to high levels of oxidative stress and consequently, apoptotic
cell death.67 Several copper(II) complexes reported in the litera-
ture were shown to induce nrf2 activation. Copper(II) diethyl-
dithiocarbamate activated nrf2 in vascular endothelial cells in
contrast to structurally analogous Fe and Zn complexes, while
CuSO4 and diethyldithocarbamate proligand on their own
failed to induce nrf2 upregulation.62,68 Diacetyl-bis(N4-methyl-
thiosemicarbazonato)copper(II) [CuIIATSM] was reported to
induce expression of antioxidant enzymes through activation
of nrf2 and its co-activator protein DJ-1 in response to oxi-
dative stress both in vitro and in vivo.69 Recently, Newton et al.
developed a copper(II)–TSC complex NSC689534 with ROS-
inducing and GSH-depleting properties which was subjected
to microarray analysis.62 It was demonstrated that NSC689534
activated several ROS-connected pathways, including a number
of genes involved in nrf2-mediated oxidative stress.62
Since 1–4 induced significant ROS production, we investi-
gated the expression of nrf2 in MDA-MB-231 cells following
exposure. Since the induction of ROS species started at early
time points, the cells were exposed to the complexes and
NaH2L
Et proligand at the indicated concentrations for 24 h.
Subsequently, nrf2 expression was determined by western blot.
As can be seen in Fig. 8, all complexes induced marked
expression of nrf2 in a concentration-dependent manner and
the stronger upregulation corresponded to the IC50
concentrations.
For further validation, we also examined p21 expression.
P21 is a cyclin-dependent kinase (cdk) inhibitor that is known
to be a major target of p53-mediated cell cycle arrest.70 Upon
Fig. 7 Detection of ROS with H2DCF-DA (20 µM) after exposure of MDA-MB-231 cells to (A) TBHP (positive control), trolox (ROS scavenger) and
complexes 1–4 at indicated concentrations, (C) complexes 1–4 at indicated concentrations and corresponding complexes pretreated with trolox,
(D) complexes 1–4 at indicated concentrations with corresponding TSC proligands. Values are means ± standard deviations from at least three inde-
pendent reproducible experiments with exposure time 5 h. (B) Representative histograms showing the increase of the DCF ﬂuorescence upon treat-
ment with 1.
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DNA damage of cancer cells by cytotoxic compounds, p21 acti-
vates cell cycle arrest between G1 and S phase to allow cells
complete DNA repair before proceeding to another phase of
the cell cycle. It was reported that p21 enhanced cell survival
by upregulation of nrf2-mediated antioxidant defense.71,72 As
expected, the levels of p21 protein were upregulated in dose-
dependent manner in agreement with nrf2 upregulation.
Additionally, we tested the eﬀects of 3 in comparison with the
corresponding proligand NaH2L
Et at similar concentrations
and found that alone, NaH2L
Et did not induce any antioxidant
response in MDA-MB-231 cancer cells. The results showed con-
clusively the key role of copper(II) for the cytotoxic activity of
this class of complexes and implicated ROS induction as the
underpinning mode of action.
Conclusions
Four water-soluble sulfonated thiosemicarbazones as sodium
salts NaH2L
H, NaH2L
Me, NaH2L
Et and NaH2L
Ph and four new
copper(II) complexes 1–4 have been synthesised and character-
ised by analytical and spectroscopic techniques. The crystal
structures of complexes 1–3 were established by single crystal
X-ray crystallography. The antiproliferative activity of all com-
pounds was tested against various cancer cell lines with
diﬀerent resistance to chemotherapy. Whereas all thiosemicar-
bazones were noncytotoxic within all the concentrations
tested, copper(II) complexes demonstrated marked antiproli-
ferative activity. The mode of action of copper(II)–thiosemicar-
bazone complexes might be related to the induction of severe
oxidative stress, as they were shown to significantly induce
ROS in cancer cells at early time points and promote nrf2-
mediated antioxidant defense. The results clearly demon-
strated the role of copper(II) center in the mechanism of action
of new complexes.
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